Ardelyx Inc (NASDAQ:ARDX) has coverage initiated with a Overweight rating

Analyst Ratings For Ardelyx Inc (NASDAQ:ARDX)

Story continues below

Today, Piper Jaffray Companies initiated coverage on Ardelyx Inc (NASDAQ:ARDX) with a Overweight.

There are 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Ardelyx Inc (NASDAQ:ARDX) is Buy with a consensus target price of $9.00 per share, a potential 175.23% upside.

Some recent analyst ratings include

  • 4/8/2019-Ardelyx Inc (NASDAQ:ARDX) has coverage initiated with a Overweight rating
  • 8/24/2018-Ardelyx Inc (NASDAQ:ARDX) has coverage initiated with a Buy ➝ Buy rating and $7.00 price target
  • 3/19/2018-Ardelyx Inc (NASDAQ:ARDX) had its Outperform ➝ Outperform rating reiterated by Leerink Swann with a $13.00 price target
  • 3/15/2018-Ardelyx Inc (NASDAQ:ARDX) had its Outperform rating reiterated by Wedbush
  • On 1/2/2019 David P Rosenbaum, Insider, sold 5,585 with an average share price of $1.70 per share and the total transaction amounting to $9,494.50.
  • On 1/2/2019 Elizabeth A Grammer, EVP, sold 4,920 with an average share price of $1.70 per share and the total transaction amounting to $8,364.00.
  • On 1/2/2019 Mark Kaufmann, CFO, sold 6,556 with an average share price of $1.70 per share and the total transaction amounting to $11,145.20.
  • On 1/2/2019 Michael Raab, CEO, sold 19,644 with an average share price of $1.70 per share and the total transaction amounting to $33,394.80.
  • On 11/13/2018 David P. Rosenbaum, Insider, sold 5,570 with an average share price of $2.84 per share and the total transaction amounting to $15,818.80.
  • On 11/13/2018 Elizabeth A. Grammer, EVP, sold 6,539 with an average share price of $2.84 per share and the total transaction amounting to $18,570.76.
  • On 11/12/2018 Scott D Sandell, Major Shareholder, sold 592 with an average share price of $2.98 per share and the total transaction amounting to $1,764.16.

About Ardelyx Inc (NASDAQ:ARDX)
Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia; RDX8940, an oral TGR5 agonist; RDX011, a NHE3 inhibitor; and RDX023 program for the development of gut-biased farnesoid X receptor agonists. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Recent Trading Activity for Ardelyx Inc (NASDAQ:ARDX)
Shares of Ardelyx Inc closed the previous trading session at 3,27 +0,20 6,51 % with 3.05 shares trading hands.

An ad to help with our costs